Social and Economic Factors Explain Why Black Patients Lose Less Weight After Bariatric Surgery than Other Groups
NEW YORK, June 18, 2025 /PRNewswire/ — Weight loss surgery has long been an effective treatment for the more than 40 percent of the American adults struggling with obesity. While previous studies show that Black patients lose less weight overall following bariatric surgery compared to other racial groups, less attention has been paid to the relationships between economic and social factors that may help explain differences in weight loss.
New research led by NYU Langone Grossman School of Medicine found that Black patients who underwent sleeve gastrectomy, the most common weight loss surgery, between 2017 and 2020 lost 6.2 percent less weight than their White counterparts, and 4.9 percent less than Hispanic patients, after one year. However, further analyses found that a lot more complexity and interplay between non-biological factors than previously known appear to impact weight loss surgery incomes.
Published online in the journal Obesity, this is the first study to investigate the relationship between a variety of economic and social factors that include income, sleep disturbances and stress, and weight loss differences among racial groups, the study authors said.
'Our findings identified variations in bariatric surgery outcomes so that we can address them and, when appropriate, offer patients individualized support that can help promote the best possible outcomes,' said Melanie Jay, MD, professor in the Departments of Medicine and Population Health at NYU Langone Health, and senior author of the study.
How the Study was Conducted
Study participants who self-identified as either Non-Hispanic Black, Hispanic, or Non-Hispanic White were recruited from NYU Langone Health Tisch Hospital and NYC Health + Hospital Bellevue Hospital from June 2017 to March 2020. The researchers measured patients' total weight loss, waist circumference, body composition, hormones, and blood glucose levels—following up with them at multiple intervals through in-clinic visits and questionnaires over two years.
Analyzing data from 297 patients, the investigators found that after surgery, non-Hispanic Black patients lost less total weight at nearly every follow-up interval compared to their Hispanic and White counterparts. Black patients also consistently reported higher sleep disturbance, perceived stress, and experiences of discrimination.
In contrast, no significant differences in total weight loss were observed between Hispanic and White patients. White patients also were found to have better long-term blood glucose control than both Black and Hispanic patients after follow-up.
'These varied associations highlight how different lived experiences and self-perceptions across racial and ethnic groups can influence surgical outcomes,' said Sally M. Vanegas, PhD, research assistant professor in the Department of Medicine and lead study author. 'Additional research is needed to better understand how a broader range of socioeconomic factors may shape these outcomes.'
José O. Alemán, MD, PhD, an endocrinologist at NYU Langone and co-senior author of the study said he and his colleagues will continue analyzing data from the study participants to explore additional biological factors that may influence weight loss surgery outcomes, including changes in gene expression and the microbiome.
'As a clinical community, we have to be honest that these differences exist, as well as reinforce the importance of adopting a holistic approach to care.'
In addition to Jay, Alemán and Vanegas, additional collaborators from NYU Langone Health include Silvia Curado, PhD, Boyan Zhou, PhD, Ericka N. Merriwether, PhD, Nicholas Illenberger, PhD, Evelyn Armijos, Ann Marie Schmidt, MD, Christine Ren-Fielding, Manish Parikh, MD, and Brian Elbel, PhD.
The study was provided with institutional support from NYU Langone Health and obtained donor support through the J. Ira and Nicki Harris Family Foundation, an AHA Ignition Center Grant (17SFRN33590133), and the Clinical and Translational Science Institute (CTSI), which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445. SMV was in part supported by 2T32HL098129 from the National Heart, Lung and Blood Institute. JOA was in part supported by K08DK117064 from the National Institute of Diabetes and Digestive and Kidney Diseases and the Doris Duke Foundation. MJ was in part supported by the National Heart, Lung and Blood Institute (K24 HL165161-01A1).
About NYU Langone Health
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media Inquiries:
Sasha Walek646-501-3873Sasha.walek@nyulangone.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 days ago
- Malay Mail
Rethinking Obesity: Novo Nordisk's Latest Initiative Urges Singaporeans to Treat, Not Blame
'Beyond the Scale' focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care. Novo Nordisk's 'Beyond the Scale' initiative Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage timely, evidence-based conversations with healthcare professionals. Promote empathy and science within the medical community. Support patients with tools to take charge of their health. Visiting [ for factual resources, use a BMI measurement tool, and locate a nearest weight management healthcare professional. Starting honest conversations with GPs, nurses, and pharmacists. Sharing content to help dismantle myths and support loved ones on their health journeys. SINGAPORE - Media OutReach Newswire - 27 June 2025 -Imagine a chronic disease affecting more than 600,000 peoplein Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This is the reality of obesity today. For many, outdated perceptions and delays in care have created barriers to support and treatment. Today, a new initiative is calling for a shift — to change how we think, talk about, and respond to obesity, through a lens of science, empathy, and early intervention."Just eat less." "Try harder." "It's a lifestyle choice." These are more than just phrases — they reflect a deeper misunderstanding of obesity. Today, a bold new initiative, seeks to challenge those misconceptions and open the door to a more compassionate, evidence-based across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, but as a complex, chronic disease. The initiative invites the public to go beyond — beyond stigma, beyond myths, beyond labels — and recognise obesity for what science confirms it to be: a multifactorial health condition that deserves understanding, early intervention, and clinical by global healthcare companyin collaboration with local healthcare professionals and patient advocates, "Beyond the Scale" is a disease awareness initiative aimed at driving a shift in how individuals, communities, and healthcare providers approach obesity management."We believe it's time to shift from blame to understanding," said. "Obesity affects 1 out of 9 people in Singapore, yet it's still too often seen as a matter of willpower. The reality is that obesity is a complex, chronic disease driven by biology, environment, and unequal access to time we treat it with the seriousness it deserves — and we are proud to lead that conversation and drive meaningful change through the "Beyond the Scale" 2021–2022 National Population Health Survey reveals the highest obesity rate (15%) among adults aged 40 to 49, while 43.3% of residents aged 18 to 74 had abdominal obesity, which increases with age and peaks between 50 to 74 is compounded by the fact that perceptions persist about obesity being a personal failing, discouraging individuals from seeking help, delaying diagnosis, and compounding the health burden on families and the healthcare significantly increases the risk of, all of which already place a growing strain on Singapore's healthcare infrastructure. The economic impact is substantial: in 2019, metabolic-risk related diseases, including obesity, diabetes, hypertension, CKD, and cardiovascular conditions, cost Singapore S$2.20 this, S$642 million were healthcare expenditures, and excess weight alone accounted for an estimated S$261 million in annual medical and absenteeism decisive public health action, these obesity-related comorbidities are poised to escalate into a major societal and economic burden."This is not just a personal issue — it's a public health priority," said"We know obesity changes how the body regulates appetite, energy storage, and metabolism. It's a disease, not a choice. Science supports this — and our response should reflect it."Obesity is not simply about calories in and out. Research confirms it involves neuroendocrine (hormonal), genetic, and psychosocial factors, making it both preventable and treatableStudies show that in Singapore, weight stigma is often driven by the belief that obesity is a personal failing, lack of willpower, or lifestyle choice leading to delayed treatment, reduced care-seeking, and poorer health outcomes, particularly in managing chronic conditions such as cardiovascular and kidney disease."Beyond the Scale" is more than a slogan — it is a call toTo move away from blame, appearance-based judgments, and oversimplified narratives, toward empathy, science, and sustained health. It is an urgent appeal to rethink, retrain, and rehumanise the way we support individuals living with obesity."The earlier we intervene, the better the outcomes," said"Obesity is not a character flaw. It's a disease. And it's time we responded with the same respect, science, and care we give every other chronic condition.""Beyond the Scale" aims to:Singaporeans can participate by:1. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.2. World Obesity. Retrieved from 3. World Obesity. Retrieved from 4. Lee, Y. V., & Tan, N. C. (2014). Obesity in Singapore: An update. The Singapore Family Physician, 40(2), 11–16. 5. World Health Organization. (2024). Obesity and As accessed on 22nd May 2025.6. Ministry of Health, Singapore. (2022). National Population Health Survey 2022 Report. 7. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep. 2015 May;17(5):34. doi: 10.1007/s11906-015-0544-2. PMID: 25833456; PMCID: PMC4427189.8. Tan, V., Lim, J., Akksilp, societal cost of modifiable risk factors in Singapore.23, 1285 (2023). (2.2 Billion)9. Junxing C, Huynh VA, Lamoureux E, Tham KW, Finkelstein EA. Economic burden of excess weight among older adults in Singapore: a cross-sectional study. BMJ Open. 2022 Sep 16;12(9):e064357. doi: 10.1136/bmjopen-2022-064357. PMID: 36113947; PMCID: PMC9486358.10. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290.11. Goff AJ, Lee Y, Tham KW. Weight bias and stigma in healthcare professionals: a narrative review with a Singapore lens. Singapore Med J. 2023 Mar;64(3):155-162. doi: 10.4103/ PMID: 36876621; PMCID: #NovoNordisk The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. "Beyond the Scale" campaign builds on Novo Nordisk's long-standing commitment to tackling chronic diseases. With over 100 years of experience advancing care for diabetes and more than 25 years of focused obesity research, Novo Nordisk is pioneering the medical management of obesity and the science of the GLP-1 hormone — a naturally occurring signal that regulates appetite and plays a key role in achieving sustained weight loss. As part of its mission to drive long-term health outcomes, Novo Nordisk is also investing in scalable prevention efforts. Through the Cities for Better Health initiative — a global public-private partnership spanning over 50 cities — Novo Nordisk is working to reduce chronic disease risk in vulnerable urban communities. Its latest programme, the Childhood Obesity Prevention Initiative (COPI), delivers targeted interventions to promote healthier diets and physical activity among children aged 6–13 in underserved areas. In Singapore and beyond, these initiatives reinforce Novo Nordisk's holistic approach: treating obesity with medicine and empathy today, while building healthier environments for the next generation. For more information, visit
New Straits Times
2 days ago
- New Straits Times
#NSTviral: UTM student's rocketry dream takes flight in US, wins hearts online
KUALA LUMPUR: A video of a Universiti Teknologi Malaysia (UTM) student expressing pride in competing at the world's largest rocketry competition in the US has gone viral, drawing widespread praise and admiration online. In the 22-second TikTok clip, @niki_dnsh shared that his team was the only Malaysian group participating in the prestigious rocketry event held on American soil. "This is the peak of my university life. Who would have thought I'd set foot in the US at 23? "After months of hard work, sleepless nights and countless setbacks, we finally made it to the US. "It is truly an honour to represent my country. All gratitude to Allah for granting me the opportunity and resilience to persevere through every challenge," he said. The video has since garnered over 100,000 views, with TikTok users flooding the comments section with messages of encouragement, particularly from UTM alumni and Malaysians inspired by the team's achievement. User @Msaifithnain76 commented: "The government should take note of this and see its potential for national defence. Invest in our capabilities." Another user, @Rose, wrote: "Representing the entire country with a multiracial team like no other. Always proud to be Malaysian."
Malaysian Reserve
2 days ago
- Malaysian Reserve
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ — USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Citius Oncology, Inc. (NASDAQ: CTOR), ADC Therapeutics SA (NYSE: ADCT), and OS Therapies Incorporated (NYSE-American: OSTX). The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.' Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. 'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.' Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a strategic partnership with Fosun Pharma to accelerate development of TEV-56278, a novel anti-PD1-IL2 immunotherapy designed using its proprietary ATTENUKINE™ technology. 'This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline,' said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. 'TEV-56278 demonstrates the strength of Teva's innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.' This investigational fusion protein is aimed at selectively delivering IL-2 to PD-1+ T cells, potentially enhancing anti-tumor response while limiting toxic side effects. Under the agreement, Fosun will lead clinical, manufacturing, and commercial activity in China and parts of Southeast Asia, while Teva retains global rights elsewhere. Citius Oncology, Inc. (NASDAQ: CTOR) recently announced that it expects to commercially launch LYMPHIR™ in 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), pending FDA approval. 'We've made steady and meaningful progress toward commercialization over the past several months,' said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. 'With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community.' ADC Therapeutics SA (NYSE: ADCT) recently reported updated Phase 2 data from an investigator-initiated trial of ZYNLONTA® in relapsed/refractory marginal zone lymphoma (r/r MZL), showing an 84.6% overall response rate and a 69.2% complete response rate. 'Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites.' said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. 'As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available.' The trial also showed encouraging durability, with complete responses maintained in 17 of the 18 patients who achieved a complete response and progression-free survival of 92.9% at 12 months. ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile. OS Therapies Incorporated (NYSE-American: OSTX) received positive written feedback from the FDA following a Type D meeting regarding its lead candidate, OST-HER2, for pediatric lung metastatic osteosarcoma. 'We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ,' said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. 'Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting.' The agency supported the company's proposed use of external comparators in its Phase 2b trial, potentially laying groundwork for accelerated approval. OS Therapies has submitted requests for an End of Phase 2 Meeting and Breakthrough Therapy Designation, with regulatory filings expected to advance in late 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video – – View original content:
